{"entity":{"id":"nct06703255","kind":"trial","name":"A Phase 2 Study of HX301 in Patients with High-grade Giloma","aka":[],"tldr":"A phase 1/2 trial of Temozolomide in glioma & glioblastoma, run by Hangzhou Hanx Biopharmaceuticals, Ltd., now recruiting.","summary":"A Phase 2 Study of HX301 in Patients with High-grade Giloma is a phase 1/2 interventional study registered as NCT06703255 by Hangzhou Hanx Biopharmaceuticals, Ltd., with 72 participants planned, started 2025-01-08 and due to reach its primary completion in 2026-12-31. Interventions recorded: HX301+/Temozolomide.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06703255","url":"https://clinicaltrials.gov/study/NCT06703255"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["glioblastoma"],"sections":[],"technologies":[],"targets":[],"drugs":["temozolomide"],"companies":["hangzhou-hanx-biopharmaceuticals"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT06703255","phase":"1/2","setting":"A Phase IIa Clinical Study of HX301 Alone or in Combination with Temozolomide in Patients with High-Grade Glioma (Grade III and IV)","sponsor":"Hangzhou Hanx Biopharmaceuticals, Ltd.","enrolled":72,"outcomes":[]},"route":"/trials/nct06703255/","neighbours":{"cancer":[{"id":"glioblastoma","kind":"cancer","name":"Glioma & glioblastoma","route":"/cancers/glioblastoma/"}],"drug":[{"id":"temozolomide","kind":"drug","name":"Temozolomide","route":"/drugs/temozolomide/"}],"company":[{"id":"hangzhou-hanx-biopharmaceuticals","kind":"company","name":"Hangzhou Hanx Biopharmaceuticals","route":"/companies/hangzhou-hanx-biopharmaceuticals/"}]}}